Pharmacology of calcineurin antagonists (Q35710811)

9 August 2017

1 reference

title

Pharmacology of calcineurin antagonists (English)

1 reference

9 August 2017

1 reference

Kapturczak MH

1

1 reference

9 August 2017

Meier-Kriesche HU

series ordinal

2

1 reference

9 August 2017

Kaplan B

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Transplantation Proceedings

9 August 2017

1 reference

9 August 2017

36

1 reference

9 August 2017

2 Suppl

1 reference

9 August 2017

25S-32S

1 reference

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Biological effects of cyclosporin A: A new antilymphocytic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin A in patients receiving renal allografts from cadaver donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin A for the treatment of graft-versus-host disease in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Clinical use of tacrolimus (FK-506) in infants and children with renal transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

NF-AT components define a family of transcription factors targeted in T-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Transcription factors of the NFAT family: regulation and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporine induces the expression of the cyclin inhibitor p21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Immunosuppressants: cellular and molecular mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Mechanisms of action of cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The regulation of AP-1 activity by mitogen-activated protein kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin pharmacokinetics in paediatric transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Effect of bile on cyclosporin absorption in liver transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin clinical pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Practical aspects in the use of cyclosporin in paediatric nephrology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Pharmacokinetics of oral cyclosporin A in diabetic children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Concentrations of cyclosporin A and its metabolites in human tissues postmortem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

High-fat meals increase the clearance of cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin metabolism by human gastrointestinal mucosal microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Cyclosporin metabolism in transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The synergistic immunosuppressive potential of cyclosporin metabolite combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The presence of cyclosporine in body tissues and fluids during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Breast-feeding during treatment with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Clinical pharmacokinetics of tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Clinical management of tacrolimus drug interactions in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Mechanisms of clinically relevant drug interactions associated with tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Dexamethasone modulation of multidrug transporters in normal tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Clinically significant drug interactions with cyclosporin. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Early clinical experience with a novel rapamycin derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Current opinions on therapeutic drug monitoring of immunosuppressive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Evidence that calcineurin is rate-limiting for primary human lymphocyte activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

The temporal profile of calcineurin inhibition by cyclosporine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Pharmacokinetics of tacrolimus in liver transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.01.018

10.1016/J.TRANSPROCEED.2004.01.018

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference